Biovail acquires Ampakine compounds from Cortex Pharma for respiratory depression treatment (PharmaBiz)
Biovail Corporation announced that its subsidiary, Biovail Laboratories International SRL (BLS), has acquired certain Ampakine compounds, including associated intellectual property, from Cortex Pharmaceuticals, Inc. (Cortex) for use in the field of respiratory depression, a brain-mediated breathing disorder.
Related posts:
- Cortex Sells Selected AMPAKINE Compounds And Rights To Respiratory Depression Indication To Biovail (Medical News Today)
- Depression: It’s uplifting for Big Pharma
- Deep Brain Stimulation for Major Depression: Miracle therapy or just another treatment?
- Naturopathic Treatment Can be Safely Combined with TMS for Treatment of Depression
- Electrical ‘deep brain’ depression treatment safe, effective: research